This review covers biosensors based on piezoelectric crystals, optical systems, field effect transistors and thermistors. Piezoelectric crystal or microgravimetric biosensors have been used for immunoassay. Optical biosensors are described in which waveguides are used to transmit changes in optical characteristics or, in an innovative mode, the evanescent wave component of a completely internally-reflected light beam is used to study optical changes. Optical biosensors have been used in immuno and in enzyme-based assays. Field effect transistors detect changes in ion concentrations and have been applied to the detection of biochemical reactions which involve a change in concentration of a specific ion. Thermistors are used to monitor the heat produced as the result of an exothermic enzymatic reaction and this has been applied to the assay of compounds or enzymes of interest. Biosensors may find a role in clinical biochemistry in low' volume testing, patient self-testing and in vivo monitoring.
Biosensors are analytical devices based upon immobilised biological molecules on the surface of microelectronic transducers. Most publications about them have dealt with enzymeelectrode based sensors which involve the use of pH electrodes, amperometric devices, ionselective electrodes or oxygen electrodes and these have been the subject of several reviews and overviews. I. 2. 3 In contrast, this review is concerned with piezoelectric crystal, optical, field effect transistor and thermistor biosensors and particularly their application to clinical biochemistry.
The potential advantages of biosensors are that they require biological sensing material, which is often very expensive, in only minute amounts, and their sensitivity and selectivity may be further enhanced electronically by microcircuitry. Miniaturisation should reduce cost, and may be one factor which will allow these devices to be developed for in vivo monitoring.
Piezoelectric crystal biosensors
A quartz piezoelectric crystal oscillator is a low-cost, frequency standard used in electronic equipment. It consists of a small quartz wafer on to which two metal electrodes are deposited.
The piezoelectric material is capable of oscillating when placed in an appropriate electronic circuit and the frequency of resonance is changed on altering the mass on the surface of the crystal. Publications of clinical interest citing the use of piezoelectric crystals have been immunoasssays in which the crystal is precoated with either the antigen or the antiserum and then exposed to the complimentary antiserum or antigen. The binding of the antigen and antibody causes a change in mass on the surface of the crystal and this mass change is detected by a change in the frequency of resonance of the crystal. The relationship is given by the Sauerbrey equation:
where Df/f is the change in frequency (Hz), Dm is the change in mass (g), A is the area covered by the adsorbed material (cm 2 ) , p is the density of the quartz (g/cm') and t is the thickness (em) of the uncoated crystal. Shons, Dorman and Najarian" describe a technique in which a crystal was coated with serum albumin or y-globulin, the crystal frequency was measured, the coated crystal was then exposed to the appropriate antiserum, and the shift in fre-559 quency due to the adsorption of the antiserum measured. In a typical experiment, the crystal was first coated with bovine serum albumin (BSA) then exposed to various concentrations of rabbit anti-BSA. It was possible to distinguish between dilutions of antiserum in the range 111000 to full strength antiserum. In 1980 a patient? was filed on a similar biosensor in which the crystal was coated with the antigen or a protein mixture containing the antigen. The antigen-coated crystal was contacted with a liquid sample and a pre-determined amount of an antibody specific for the antigen was determined. The antigen in solution and that on the crystal compete for binding with the antibody. The amount of free antigen in the serum could be detected by measuring the change in frequency of the crystal and referring to a standard curve. It was claimed that the technique could distinguish solutions containing 8 mg/L of a specific immunoglobulin. Shons et al," claimed the piezoelectric crystal microbalance provided similar discrimination between different dilutions of antiserum to those obtained using a passive agglutination technique. The passive agglutination technique required hours but the results from the crystal could be obtained in minutes. In both the systems described, there was a need to pursue an extensive rinsing and drying procedure before the change in frequency could be assessed; however, Roederer and Bastiaans" describe a system in which an antibody was immobilised on the quartz crystal surface and this was exposed to the antigen in borate-buffered saline. The change in frequency was measured while the crystal was still in contact with the solution and this change was compared to that of a reference crystal which was exposed to a similar solution without the antigen. The difference in response between the reference crystal and the crystal exposed to the antigen was found to be proportional to the concentration of antigen present. The study was extended to include the detection of IgG in dilute serum and no significant difference was found between the response to the antigen in dilute (11100) serum and antigen in boratebuffered saline. The antigen could be removed from the antibody-crystal surface using a solution of high ionic strength, so it was possible to use a crystal for many analyses, until the antibody gradually broke away. However, the system lacked sensitivity. The limits of detection were poor due to nonspecific adsorption at both the indicator and reference crystals. Another limitation is that the analyte must have a high molecular weight. Microgravometric assay systems are unlikely to be appropriate for low molecular weight molecules such as many drugs.
Optical biosensors
There have been a number of papers and reviews describing the use of fibre optics for in vivo and in vitro determinations/"!" but few have described biosensors in which a biological molecule is linked directly to the fibre-optic probe. However, Freeman and Seitz!" developed a probe in which peroxidase and luminol were immobilised in gel on the end of a fibre optic. The chemiluminescence produced in the presence of hydrogen peroxide was detected.
Schultz, Mansouri and Goldstein 17 constructed a prototype fibre-optic probe based upon competitive binding in which a metabolite and a fluorescein-labelled analogue, in this case glucose and labelled dextran, compete for binding to the protein Concanavalin A. The labelled dextran was displaced by glucose and could diffuse into the field of view of the detector. This prototype probe was able to detect glucose in the physiological range but the sensitivity was poor due to a high baseline response and the response time for the sensor was slow at 10 min. Goldfinch and Lowe " described a simple solid-phase optoelectronic sensor in which triphenylmethane dyes such as bromocresol green and bromothymol blue were immobilised in conjunction with appropriate enzymes on a transparent membrane. These membranes could be applied to the end of a fibre optic. iij In the presence of the substrate, the catalytic action of the enzyme perturbed the local pH and caused a characteristic colour change in the dye. Penicillase, urease and glucose oxidase have been incorporated into this system and 0-10 mM penicillin G, urea and glucose in 1 mM phosphate buffer have been determined. The system is dependent upon a pH change and therefore the buffering capacity of the applied sample must be limited for the system to function.
The volume of the reagents immobilised on the tip of a fibre optic probe is small and the reaction area being studied is small, but it is possible to increase the latter by monitoring reactions or changes along the side of a waveguide such as a fibre optic, glass capillary or microscope slide. The reagents are coated onto the waveguide, the evanescent component of the completely internally-reflected light beam enters the coating and there is interaction in this very thin layer. In this mode the transmission properties of the waveguide are modified using a change in the refractive index at the interface with the guide surface. This changes the critical angle for the internal retlectance.r" This mode has been used for an immunoassay of human immunoglobulin G. 21 Antiserum was adsorbed onto the surface of an optical waveguide and the immobilised antibody was reacted with a solution containing antigen. The growing antigen-antibody layer resulted in an increase in the scattered light which was monitored by a photomultiplier at right angles to the direction of the light passing through the waveguide. Measurements took about 5 min and the limit of sensitivity achieved with human IgG was 10 nmoUL. In a further development of the use of the evanescent wave component, methotrexate was bound to the antibody on the surface of a slide waveguide. 22 The amount of methotrexate was monitored by the decrease in transmittance at 310 nm measured at the waveguide output. The system was able to detect 270 nmoUL. IgG was also assayed using a two-site 'sandwich' immunoassay in which a second fluoresceinlabelled antibody was bound to the antigen. The label was monitored by the increase in signal at 520 nm at the waveguide output. This assay was applied to a slide waveguide and to a fibre optic. It was possible to detect as little as 30 nmol/L IgG. The immunoassays were monitored kinetically and could be completed in 15 min.
Field effect transistor (FET) biosensors
In a conventional FET, charge movement is controlled by an electrostatic field between a metal 'gate' and a semiconductor channel. Several sensors have been developed based on the same principle, but the gate has been replaced by membranes which allow the passage of selected ions or which contain immobilised enzymes. These enzymes give rise to a change in electrical field, usually due to a change in H+ concentration. An increase in charge density, due to the accumulation of specific ions, is modulated through the insulated material of the field effect transistor and this changes the characteristics of the semiconductors to allow current to flow between the source and the drain of the transistor.
The chemical-sensitive or ion-selective FETs,
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while not strictly biosensors as they do not involve any immobilised biological molecule, have been used to measure plasma Na+, Ca2+, K+ and pH. 23 An ammonia-sensitive palladium metal-oxide semiconductor (Pd-MOS) has been applied to the detection of biochemical reactions involving ammonia.P Examples are the determination of urea and creatinine using urease and creatinine deiminase, respectively.P The enzymes are not applied directly to the Pd-MOS but immoblised on controlled pore glass and the ammonia generated is collected in a gas stream and passed to the heated Pd-MOS.
Urea has also been assayed by using a pH-sensitive FET coupled with cross-linked urease-albumin membranes.i" This device could be used to assay urea solutions between 0·05 mM and 10 mx, The sensitivity and the speed of the assay depended upon the thickness of the enzyme membrane. Caras and Janata 27 describe a penicillin-sensitive enzyme FET based upon a cross-linked penicillinase-albumin layer over a pH sensitive ion-sensitive FET. Sensitivity to temperature and ambient pH change was minimised by using it in a differential mode; however, the buffering capacity of the test solution affected the sensitivity of the system.
Thermistor biosensors
In this sensor the heat generated by exothermic enzymatic reactions is measured. Most enzymatic reactions are accompanied by heat evolution in the range of 5-100 kJ/mol and typically temperature changes in the range of 1O-2·C are rnonitored.P This principle has been used in a flow-through mode in a wide range of analyses of clinically important compounds (see Table) . The enzyme was immobilised on support particles in a small column surrounding or leading to the thermistor. Sample volumes may be as low as 10~L and the system may have a capacity of about 30 samples per h. The sensitivity obtained has been shown to be adequate at least for clinical applications. Guilbault et al. 29 describe an enzyme thermistor for blood alcohol determination in which alcohol oxidase is immobilised on to glass beads in a flow-through system which is monitored using a thermistor. The system, which has been used for whole blood assays, can detect as little as 0·2 mM methanol, ethanol or butanol, with linearity to 2·0 rna, Unfortunately, the enzyme used did not distinguish between the different alcohols. The thermistor system has been modified for the assay of soluble enzyrnes.P'' but this does not involve the immobilisation of a biological molecule and therefore falls outside the strict scope of this review. An alternative application of thermistor biosensors is in an immunosorbent assay which has been named 'thermometric enzyme-linked immunosorbent assay' (TELISA)Y The column is filled with an immunosorbent such as antibodies immobilised on Sepharose CL 4B. The antigen to be determined and an enzymelabelled antigen are introduced into the flow. A portion of the labelled antigen will be bound and this will lead to a heat-producing reaction when the appropriate substrate is introduced. This system has been shown to be capable of detecting 10-10 M (5 ug/L) human serum albumin and the total time for assay and regeneration was 10 min.
The application and role of biosensors
Biosensors are potentially small, accurate, fast and inexpensive analytical tools, and some enzyme--electrode based biosensors have already reached the commercial application stage for analysis of glucose and urea in clinical biochemistry.
The biological component of the biosensor gives it specificity, subject to the same limitations, such as enzyme stability and optimisation of reaction conditions, that are present in other enzyme-or antibody-based assay systems. Biosensors are often economical in the use of biological material. The sensing area of the "enzyme FET is small (0,5 mm/) and requires very little enzyme (2,5 x 10-4 IV). This could lead to a significant cost saving when expensive enzymes are required.
There are problems of interference when the measurement of pH is an integral part of the assay system. This has been particularly true with FETs systems. Fluctuating temperatures can also cause interference with some of the systems and this problem will have to be resolved. However, the problems associated with sample turbidity and pigmentation are largely overcome using the biosensors. Even the optical waveguide sensors when used in the evanescent wave component mode may be relatively immune to these problems as the bulk solution is not 'observed' in this technique, but a thin film, about 200 nm thick, at the waveguide interface is examined and this is the site where the reaction of interest takes place.
Piezoelectric crystals, fibre optics, FETs and thermistors are all used in robust sensing devices and electronic equipment. This demonstrates that, although the component may be fragile, appropriate housing can protect it. The decreasing cost of electronic components should ensure that the biosensor devices can be manufactured inexpensively in large numbers. Difficulties have been experienced in the manufacture of modified FETs. Techniques tend to be labour-intensive and there has been a high failure rate for these devices. Until the problems have been solved the devices are unlikely to make a big impact in clinical analysis.
It is doubtful whether the biosensors described in this review will compete with multistream wet-chemistry analysers in the hospital laboratory." because the hospital analysers can handle large workloads relatively inexpensively. An exception might be the thermistor biosensor. However, in spite of the potential of the microcaloric principle, this technique has not gained widespread application, possibly because of instrumentation costs or the fact that, so far, the probe has not been miniaturised to the extent attained with other types of biosensor.
Biosensors may find their place in the following situations: patient self testing and screening; assays performed at the doctor's surgery; in vivo monitoring; providing faster analytical results than can be provided by current methods, eg, in immunoassay; as an adaptation to changing ways of financing health care, as presently seen in the USA. Patients may become more involved in selfdiagnosis with less use of the central laboratory. The reduced cost in terms of sample handling and savings related to the immediate availability of results will make small, easy-to-handle biosensors an alternative to the central laboratory. Biosensors will have to compete with 'dipstick' and other patient self test kits. They will have to be inexpensive, operatorindependent; and give assay results of a quality comparable with those obtained in the laboratory.
For biosensors to find an application in in vivo monitoring of a patient's biochemical status they will have to be small, rugged and biocompatible. Problems of ongoing calibration and standardisation will have to be solved. Fibre optic sensors seem particularly attractive for in vivo monitoring as fibre optics have already found an extensive application in internal inspection procedures in medicine. Also, fibre optic sensors may have electric connec-
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tions remote from the sensing component and, therefore, away from contact with the patient.
It will be interesting to monitor the future development of biosensors to see if they do offer a tool to aid in quick diagnosis, selfmonitoring and screening.
